Skip to main content
 
January 7, 2015
Companies to explore promise of CRISPR as a drug discovery research tool

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced that it entered into a collaboration agreement with Novartis under which the two companies will utilize Caribou's proprietary CRISPR-Cas9 platform to research new CRISPR-based drug target screening and validation technologies.

November 18, 2014
Newly formed company has licensed Caribou technology to advance CRISPR-Cas9 for therapeutic development

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced the launch of Intellia Therapeutics, a new company created by Caribou and Atlas Venture. Intellia will utilize Caribou’s proprietary CRISPR-Cas9 gene editing and repair technology platform in the development of new therapies targeting a variety of genetic-based diseases.

Pages